Ongoing studies suggest an important role for iPLA 2 b in a multitude of biological processes and it has been implicated in neurodegenerative, skeletal and vascular smooth muscle disorders, bone formation, and cardiac arrhythmias. Thus, identifying an iPLA 2 binhibitor that can be reliably and safely used in vivo is warranted. Currently, the mechanism-based inhibitor bromoenol lactone (BEL) is the most widely used to discern the role of iPLA 2 b in biological processes. While BEL is recognized as a more potent inhibitor of iPLA 2 than of cPLA 2 or sPLA 2 , leading to its designation as a ''specific'' inhibitor of iPLA 2 , it has been shown to also inhibit non-PLA 2 enzymes. A potential complication of its use is that while the S and R enantiomers of BEL exhibit preference for cytosol-associated iPLA 2 b and membrane-associated iPLA 2 c, respectively, the selectivity is only 10-fold for both. In addition, BEL is unstable in solution, promotes irreversible inhibition, and may be cytotoxic, making BEL not amenable for in vivo use. Recently, a fluoroketone (FK)-based compound (FKGK18) was described as a potent inhibitor of iPLA 2 b. Here we characterized its inhibitory profile in beta-cells and find that FKGK18: (a) inhibits iPLA 2 b with a greater potency (100-fold) than iPLA 2 c, (b) inhibition of iPLA 2 b is reversible, (c) is an ineffective inhibitor of achymotrypsin, and (d) inhibits previously described outcomes of iPLA 2 b activation including (i) glucose-stimulated insulin secretion, (ii) arachidonic acid hydrolysis; as reflected by PGE2 release from human islets, (iii) ER stress-induced neutral sphingomyelinase 2 expression, and (iv) ER stress-induced beta-cell apoptosis. These findings suggest that FKGK18 is similar to BEL in its ability to inhibit iPLA 2 b. Because, in contrast to BEL, it is reversible and not a non-specific inhibitor of proteases, it is suggested that FKGK18 is more ideal for ex vivo and in vivo assessments of iPLA 2 b role in biological functions. 
Introduction
Phospholipases A 2 (PLA 2 s) catalyze hydrolysis of the sn-2 substituent from membrane phospholipids [1] . To date, 16 distinct groups of PLA 2 s are recognized [2, 3] and they include secretory (sPLA 2 s), cytosolic (cPLA 2 s), and Ca 2+ -independent (iPLA 2 s) enzymes. Of these, the Group VI iPLA 2 s are the most recently described and the least well characterized. The iPLA 2 was first purified from macrophages in 1994 [4] and subsequently cloned from multiple sources between 1997 and 1999 [5] [6] [7] . This enzyme localized to the cytosol under basal conditions is designated iPLA 2 b. Subsequently, a membrane-associated enzyme was identified and designated as iPLA 2 c. More comprehensive reviews of the iPLA 2 enzymes can be found elsewhere [8] [9] [10] [11] [12] .
Since its original description in heart and pancreas, the iPLA 2 b has been proposed to participate in membrane phospholipid remodeling, signal transduction, cell proliferation, inflammation, and apoptosis [8] [9] [10] [11] [12] . Its dysregulation has been associated with several neurodegenerative, skeletal, and vascular smooth muscle disorders, bone formation, and cardiac arrhythmias [11] . If we are to gain a greater understanding of the mechanism(s) by which iPLA 2 b contributes to these abnormalities, reagents that more specifically impact iPLA 2 b in vitro and in vivo are needed. Of the currently used inhibitors, iPLA 2 b is targeted by arachidonyl trifluoromethyl ketone (AACOCF 3 ), methyl arachidonyl fluorophosphonate (MAFP), and palmitoyl trifluoromethyl ketone (PACOCF 3 ); inhibitors that are sometimes used for ''selective'' inhibition of cPLA 2 [13] [14] [15] .
While siRNAs directed at iPLA 2 band now available iPLA 2 b-KO and Tg mice [16] [17] [18] have provided insight into biological processes impacted by iPLA 2 b, the majority of studies to assess the role of the iPLA 2 b isoform, have utilized the only available specific inhibitor of iPLA 2 [11] . This inhibitor, (E)-6-(bromo-methylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one, was synthesized in 1991 and was designated as a haloenol lactone suicide substrate (HELSS) [19] , but is now referred to as bromoenol lactone (BEL). The BEL is an irreversible suicide inhibitor that selectively targets iPLA 2 enzymes and has little or no effect on cPLA 2 or sPLA 2 activity [19] [20] [21] .
Over the years, BEL has been used to discern the involvement of iPLA 2 in biological processes and, to date, is still considered the only available specific irreversible inhibitor of iPLA 2 . Recently, the S-and R-enantiomers of BEL have been demonstrated to exhibit specific inhibition of iPLA 2 b and iPLA 2c , respectively [22] . However, several examples of inhibition of non-PLA 2 enzymes by BEL have been described [21, [23] [24] [25] [26] and the mechanism of inhibition does not appear to involve the active site of iPLA 2 [27, 28] . Although BEL treatment results in covalent modification of iPLA 2 b [14, 19] , the modified residues are cysteines and not the active site serine, likely due to a diffusible bromoketomethyl acid that is generated when iPLA 2 acts on the inhibitor [28] .
However, several features of BEL decrease its feasibility for in vivo use: (a) irreversible inhibition of iPLA 2 , (b) inactivation of other serine proteases, and (c) high toxicity due to its interaction with cysteines. For these reasons, recent efforts were directed towards synthesizing alternative compounds that can specifically inhibit iPLA 2 . Assays for PLA 2 activity in the presence of these compounds have led to the identification of fluoroketone (FK)-based compounds as potential inhibitors of the iPLA 2 enzyme group [29] . Because FK inhibitors target serine active sites they could potentially also inhibit cPLA 2 s. However, modification of the FK group along with addition of a hydrophobic terminus connected by a medium-length carbon chain to mimic the fatty acid chain conferred selectivity of the FK compounds for iPLA 2 versus sPLA 2 or cPLA 2 [29] . Among the ones tested, FKGK18 ( Fig. 1 ) was found to be the most potent inhibitor of GVIA iPLA 2 and was 195 and .455 times more potent for GVIA iPLA 2 than for GIVA cPLA 2 and GV sPLA 2 , respectively.
While the above study demonstrated the potential of FKGK18 in inhibiting iPLA 2 b, the biochemical assays were performed using human Group VIA enzyme purified from Sf9 cells [30] . Thus, it is not known whether FKGK18 is able to inhibit iPLA 2 b in biological systems. Recently, earlier generation of FK compounds (FKGK11 and FKGK2) were found to be effective in ameliorating experimental autoimmune encephalomyelitis, however, there was no demonstration of iPLA 2 b inhibition by these compounds [31] . Our work reveals that iPLA 2 b is predominantly expressed in pancreatic islet beta-cells [32] and that its prolonged activation promotes beta-cell apoptosis [33] [34] [35] [36] . Because this process is a major contributor to beta-cell dysfunction in diabetes, we sought ways to inhibit iPLA 2 b as a means to preventing beta-cell apoptosis. Though FKGK11 in now commercially available, it has been reported to be 7-fold less potent than FKGK18 in inhibiting iPLA 2 [29] . If the FKGK18 compound were an effective inhibitor of beta-cell iPLA 2 b, it would allow us to utilize it to prevent betacell apoptosis in vivo. In the present study, we therefore set out to characterize the ability of FKGK18 to inhibit iPLA 2 b using INS-1 cells overexpressing iPLA 2 b (OE), rodent myocardial preparations, and human pancreatic islets.
Results

FKGK18 inhibits iPLA 2 b similar to S-BEL
To test the ability of FKFK18 to inhibit iPLA 2 b activity, INS-1 insulinoma cells overexpressing iPLA 2 b (OE) were used. Cytosol from the OE cells was prepared and activity in 30 mg protein aliquots was assayed in the presence of varying concentrations of FKGK18. As seen in Fig. 2, FKGK18 inhibited Ca 2+ -independent PLA 2 activity in a concentration-dependent manner, similar to S-BEL, which preferentially inhibits cytosol-associated iPLA 2 b [22] . The calculated IC50 (,5610 28 M) for FKGK18 was similar to that of S-BEL [6] . In contrast, R-BEL, which inhibits membrane-associated iPLA 2 cwas a weaker inhibitor of iPLA 2 enzymatic activity, as reflected by an estimated IC50 of 3610 26 M. These findings suggest that FKGK18 is equipotent to S-BEL as an in vitro inhibitor of cytosol-associated Ca 2+ -independent PLA 2 activity, which is manifested by iPLA 2 b.
To confirm FKGK18 ability to inhibit iPLA 2 b, cytosol was prepared from myocardial tissues isolated from WT and iPLA 2 b-KO mice [37] . As illustrated in Fig. 3 , cytosol-associated Ca 2+ -independent PLA 2 activity in the WT group is stimulated by ATP, a characteristic of iPLA 2 b [32], nearly 5-fold and such stimulation was inhibited by FKGK18. In contrast, Ca 2+ -independent PLA 2 activity 6 FKGK18 in the iPLA 2 b-KO group was barely above background. These findings suggest that the myocardial cytosolassociated activity is manifested by iPLA 2 b and that it is inhibitable by FKGK18.
FKGK18 inhibits membrane-associated iPLA 2 activity similar to R-BEL
Because the putative mechanism of FKGK18 inhibition is through interaction with the lipase consensus sequence of iPLA 2 , we examined whether FKGK18 also exhibited a similar inhibitory profile against iPLA 2 c. We chose the myocardial membrane preparation because it is predominantly enriched in iPLA 2 c activity [38] . Hearts from WT mice were isolated, membrane fraction prepared, and the inhibitory effects of R-BEL and FKGK18 on iPLA 2 c activity were compared. As seen in Fig. 4A , activity is similarly inhibited in a concentration- dependent manner by R-BEL and FKGK18 with an IC50 of ,1-3 mM. To confirm that the inhibition is of activity manifested by iPLA 2 c, membrane fractions were prepared from hearts of iPLA 2 b-KO mice. As shown in Fig. 4B , FKGK18 inhibited membrane-associated iPLA 2 activity similar to R-BEL, with an IC50,1 mM. These findings suggest that iPLA 2 c is also inhibitable by FKGK18.
2.3.
Comparison of FKGK18 inhibition of cytosol-and membrane-associated iPLA 2 Though FKGK18 exhibited an ability to inhibit both iPLA 2 b and iPLA 2 c, there was a distinct separation in the potency of the drug to inhibit the two activities. To verify localization that the cytosol and membrane preparations contained the expected isoform of iPLA 2 , cytosol and membrane preparations were processed for immunoblotting analyses using antibodies directed against iPLA 2 b or iPLA 2 c. As shown in Fig. 5A , iPLA 2 b was predominantly localized in the cytosol (Top Panel) and iPLA 2 c in the membrane (Middle Panel). Thus, the activities measured in cytosol and membrane fractions are expected to be manifested by iPLA 2 b and iPLA 2 c, respectively. As illustrated in Fig. 5B , the FKGK18 inhibitory profile of cytosol-associated iPLA 2 b activity was shifted nearly two log-units to the left of membrane-associated iPLA 2 cactivity. The IC50 of FKGK18 for inhibition of cytosolassociated activity was nearly 100-fold lower than for membraneassociated activity, suggesting that FKGK18 is a more potent inhibitor of iPLA 2 b than iPLA 2 c.
FKGK18 does not inhibit chymotrypsin like S-BEL
It has been reported that BEL inhibits other proteases [10, 11, 22] and that R-BEL is more potent than S-BEL [22] . To determine if FKGK18 non-specifically inhibits proteases, the ability of FKGK18 to inhibit a-chymotrypsin was compared with that of S-BEL. This was done by monitoring a-chymotrypsincatalyzed digestion of BSA in the presence of saturating concentrations of S-BEL or FKGK18. The peptide digests were resolved by Bis-Tris gel electrophoresis and peptide fragments derived from a-chymotrypsin activity were visualized by colloidal blue staining. As shown in Fig. 6 (Lanes 1), in the presence of inhibitors alone a protein band corresponding to full-length BSA (70 kDa) is evident. However, in the presence of enzymes alone, BSA digestion in complete, as reflected by the absence of intact BSA (Lanes 2). Inclusion of FKGK18 with the enzymes also resulted in near completed digestion of BSA (Lanes 3). In contrast, inclusion of S-BEL with the enzymes, inhibited BSA digestion, as evidenced by visualization of the full length BSA (Lanes 4). These findings suggest that, unlike S-BEL, FKGK18 is not a non-specific inhibitor of non-iPLA 2 proteases.
FKGK18 inhibition of iPLA 2 b is reversible
Because BEL inhibition of iPLA 2 b is irreversible [19] , we examined the duration of iPLA 2 binhibition following a single exposure to FKGK18. INS-1 OE cells were treated with FKGK18 (10 25 M) for up to 48 h and cytosol was prepared and assayed for residual iPLA 2 b activity. As shown in Fig. 7 , activity measured following FKGK18 exposure from 2 to 48 h was similarly stimulated by ATP, indicating preservation of a viable iPLA 2 b activity. However, neither basal nor ATP-stimulated activity in cytosol prepared from cells treated with FKGK18 from 2 to 48 hours was inhibited. These findings raise the possibility that the interaction of FKGK18 with the enzyme is disturbed during preparation of cytosol, thus restoring native enzyme activity, suggesting that FKGK18 is not an irreversible inhibitor of iPLA 2 b.
FKGK18 inhibits glucose-stimulated insulin secretion (GSIS) and PGE2 generation
The reversible nature of inhibition raised the question of whether FKGK18 would be an effective inhibitor of biological processes in beta-cells that were previously demonstrated to be susceptible to inhibition by S-BEL. We previously reported that GSIS and hydrolysis of arachidonic acid (AA) from beta-cell membrane phospholipids, reflected by increases in medium content of PGE2, a metabolized product of AA, are inhibited by BEL. We therefore treated human islets with glucose in the absence or presence of FKGK18 and measured insulin secretion and PGE2 release into the media. As illustrated in Fig. 8A , insulin secretion was increased nearly 2.5-fold in the presence of 20 mM glucose (20G), relative to basal concentration of glucose (5 mM). In the presence of FKGK18, there was no change in basal insulin secretion. In contrast, stimulated insulin secretion was significantly decreased to basal levels. In parallel with GSIS, PGE2 content in the medium was significantly increased in the presence of 20G (Fig. 8B) . This is consistent with glucose-stimulated PLA 2 bcatalyzed hydrolysis of arachidonic acid from beta-cell membranes and its metabolism to PGE2, as reported earlier [39] [40] [41] [42] . As with GSIS, presence of FKGK18 did not inhibit PGE2 generation under basal conditions but significantly reduced stimulated PGE2 release into the media. These findings suggest that FKGK18 inhibits GSIS from pancreatic islets and AA hydrolysis from betacell membranes and importantly that FKGK18 can penetrate intact islets and the beta-cells contained within the islets.
FKGK18 inhibits ER stress-induced increase in neutral sphingomyelinase 2 (NSMase2)
We previously also demonstrated that iPLA 2 b activation during ER stress induces NSMase in insulinoma cells and human and mouse pancreatic islet beta-cells by an iPLA 2 b-dependent mechanism and that this process participates in beta-cell apoptosis [33] [34] [35] 37, 43] . To examine if FKGK18 inhibits NSMase2 expression, we treated INS-1 OE cells with thapsigargin to induce ER stress in the absence and presence of FKGK18 and examined expression of NSMase2 message. Because our earlier work revealed near optimal increase in NSMase 2message and protein at 8-12 h and ER stress-induced beta-cell apoptosis at 24 h, we examined NSMase2 mRNA at 8 and 24 h. As previously observed, NSMase2 was induced by thapsigargin by 8 h (Fig. 9A) and remained higher at 24 h (Fig. 9B) . Exposure to FKGK18 (pretreatment and treatment periods) promoted a concentration-dependent inhibition of NSMase2 expression at both time points. These finding suggest that FKGK18 inhibits ER stress-induced expression of NSMase2 in beta-cells.
FKGK18 inhibits ER stress-induced beta-cell apoptosis
Our collection of work reveals that iPLA 2 bplays a role in betacell apoptosis and chemical inhibition or knockdown of iPLA 2 -battenuates this process [33] [34] [35] 37, 43] . We therefore examined the ability of FKGK18 to prevent beta-cell apoptosis following induction of ER stress. INS-1 OE cells were pretreated with FKGK18 prior to and along with thapsigargin and flow cytometry analyses were used to assess the incidence of apoptosis, as reflected by TUNEL staining. Because in INS-1 OE cells apoptosis due to ER stress occurs between 20-24 h flow cytometry analysis was performed following exposure of the cells to thapsigargin for 24 h. As shown in Fig. 10 , the incidence of apoptosis was significantly increased following induction of ER stress, relative to vehicle control. However, the presence of FKGK18 promoted a concentration-dependent decrease in ER stress-induced INS-1 OE cell apoptosis. These findings suggest that FKGK is an effective inhibitor of beta-cell apoptosis.
Discussion
Presently, discerning of iPLA 2 -mediated effects by chemical means has been approached using BEL [19, 38] . However, feasibility of using BEL in vivo is limited by the irreversible nature of the inhibition by BEL along with its non-specific and potential cytotoxicity. Recently, compounds containing a fluoroketone (FK) group have been synthesized as potential inhibitors of the PLA 2 enzymes. This led to the identification of FKGK18 (Fig. 1) as exhibiting the greatest potency to inhibit iPLA 2 [29] . Furthermore, addition of a hydrophobic terminus connected by a mediumlength carbon chain to mimic the fatty acid chain conferred selectivity of the FK compounds for iPLA 2 versus the sPLA 2 or cPLA 2 isoforms [29] . However, these studies did not distinguish between inhibition of iPLA 2 b vs. iPLA 2 c by FKGK18. Further, they did not test whether FKGK18 was an effective inhibitor of cellular iPLA 2 activity or whether it impacted biological processes, previously described to involve iPLA 2 b activation.
Our group was the first to describe iPLA 2 b in the pancreatic islets and we found that it was predominantly expressed in the beta-cells of pancreatic islets [32, 43] and that it participated in glucose-stimulated insulin secretion (GSIS) [32] . Further studies indicated that long-term activation of iPLA 2 b contributes to betacell apoptosis [33, 36, 37, 43] , raising the likelihood that iPLA 2 b activation participates in beta-cell death during the evolution of diabetes. Strengthening this possibility are the reports of increased iPLA 2 b expression in rodent models of diabetes and in human diabetes [44] [45] [46] . If we are to exploit the protective effects of inhibiting iPLA 2 b in vivo, it is necessary to utilize an inhibitor that is not irreversible or cytotoxic and we therefore set out to characterize the inhibitory profile of FKGK18 on iPLA 2 b in betacells.
Our findings comparing the cytosol-associated iPLA 2 (iPLA 2 b) and the membrane-associated iPLA 2 (iPLA 2 c) activities in iPLA 2 bINS-1 OE cells and myocardial preparations from WT and iPLA 2 b-KO mice reveal that the potency of FKGK18 to inhibit iPLA 2 b is similar to the S-enantomer of BEL whereas the potency of FKGK18 to inhibit iPLA 2 c is similar to the Renantomer of BEL. However, FKGK18 inhibits iPLA 2 b with a greater potency than iPLA 2 c; as reflected by the nearly 100-fold lower IC50 value for iPLA 2 b vs. iPLA 2 c.
Attempts to determine the duration of FKGK18 inhibition of iPLA 2 brevealed that even following exposure of INS-1 OE cells to the drug for 48 h, both basal and ATP-stimulated iPLA 2 b activities in cytosol prepared from these cells were similar to that measured in vehicle-treated cells. This is in contrast to the observation of concentration-dependent inhibition of iPLA 2 b activity when FKGK18 is added directly to cytosol preparations. Thus unlike with BEL, whose inhibition of iPLA 2 b activity in islets and INS-1 cells is close to 10-20% of control activity even after Figure 8 . Effects of FKGK18 on Glucose-Stimulated Insulin Secretion (GSIS) and PGE2 Generation in Human Pancreatic Islets. Human pancreatic islets (30/condition) were incubated in KRB containing 5 mM glucose (5G) for 1 h at 37uC under 5%CO 2 /95% air atmosphere. The medium was then replaced with 5G + DMSO or 5G + FKGK18 (10 26 M) and the islets were incubated for 1 h. The islets were then exposed to KRB medium containing 5G+DMSO, 5G+FKGK18, 20G+DMSO or 20G+FKGK18. Medium was collected after 1 h and insulin and PGE2 contents in the medium were measured by ELISA. The islets were washed in PBS (36) and islet protein concentration was determined. The data were normalized to total protein content. 24 h of exposure [47] , the findings here suggest that FKGK18 inhibition of iPLA 2 b is reversible. This most likely is a consequence of disassociation of FKGK18 from iPLA 2 b during cell lysis in the cellular fractionation process. That this is not due to an inability of the FKGK18 to enter the cell is supported by the accompanying functional analyses in islets and cells, as discussed below.
We also examined for evidence of FKGK18 inhibition of achymotrypsin, which has been identified as a suitable target for aromatic haloenol lactones resulting in its mechanism-based inhibition [48] [49] [50] [51] . In prior studies, R-BEL was determined to be a more potent inhibitor of chymotrypsin than its chiral counterpart S-BEL [22, 51] . Here, we observed that S-BEL nearly completely inhibited a-chymotrypsin-catalyzed digestion of BSA. In contrast, a-chymotrypsin-catalyzed digestion of BSA was nearly complete in the presence of FKGK18. These findings suggest that FKGK18 is not an effective inhibitor of a-chymotrypsin and imply that in contrast to BEL, it is not a non-specific inhibitor of proteases.
The mechanism of FKGK18 inhibition of iPLA 2 appears to be distinct from that of BEL. With respect to BEL, Cys651 alkylation is the covalent modification of iPLA 2 b that is responsible for loss of activity, and the alkylating species is a diffusible hydrolysis product of BEL rather than a tethered acyl-enzyme intermediate [28] . In contrast, computer modeling and deuterium exchange mass spectrometry reveal that FK compounds bind at the active lipase consensus site, mimicking binding of natural substrates [52] . The hydrophobic environment of the active site in iPLA 2 favoring high affinity of the inhibitor presumably confers the greater specificity of FK compounds for iPLA 2 versus non-iPLA 2 enzymes.
In view of these findings, we next examined whether FKGK18 can inhibit biological processes in intact insulinoma cells and human pancreatic islets. Because FKGK18 appears to be a reversible inhibitor, we assessed its impact on biological outcomes that would reflect dynamic iPLA 2 b inhibition. These included: (a) GSIS, (b) hydrolysis of arachidonic acid (AA), as reflected by PGE2 generation, (c) ER stress-induced neutral sphingomyelinase 2 (NSMase2) expression, and (d) ER stress-induced beta-cell apoptosis. As discussed below, during our descriptions of iPLA 2 b role in beta-cell function and survival, we observed that these outcomes are all inhibited by BEL.
We demonstrated that GSIS from pancreatic islets parallels iPLA 2 b-catalyzed hydrolysis of AA from the sn-2 position of betacell membranes, which are enriched in AA-containing phospholipids [39, 40] , and that both are inhibited by BEL. Glucose induces accumulation of unesterified arachidonate in islets but little of this is released into the medium [53] . However, the oxygenated arachidonate metabolite PGE2 is, and is therefore used to reflect AA accumulation in the islet [54] . Here, treatment of human islets for one hour with stimulating concentrations of glucose (20 mM) promoted significant increases in both insulin secretion and PGE2 release, relative to basal (5 mM) glucose condition. Initial studies followed the protocol previously used with BEL [41] , where FKGK18 was present for only 30 min prior to the replacement of media containing higher glucose concentrations (20 mM). With this protocol, we found that both GSIS and PGE2 release were not affected (data not shown), further supporting the reversible nature of FKGK18 inhibition. However, when FKGK18 was present during the entire stimulatory period, both GSIS and PGE2 release were reduced significantly. It therefore seems plausible to deduce that the inhibitory effects of FKGK18 on iPLA 2 b, and thus effects on GSIS and PGE2 release, are conditional upon the constant presence and exposure to FKGK18.
We also reported that prolonged ER stress promotes beta-cell apoptosis via activation of iPLA 2 b, which induces NSMase2 and accumulation of ceramides as a consequence of increased hydrolysis of sphingomyelins [34] . To determine if FKGK18 attenuates these ER stress-related outcomes, INS-1 OE cells were treated with thapsigargin to induce ER stress in the absence or presence of FKGK18. In its absence, NSMase2 message is increased significantly by 8 h and remained higher at 24 h. Presence of FKGK18 promoted a concentration-dependent decrease in NSMase2 message at both time points. Because NSMase2 increase is an early event and apoptosis is a later event, the incidence of apoptosis was assessed at 24 h. Thapsigargin, in the absence of FKGK18 promoted INS-1 OE beta-cell apoptosis, as reflected by increased TUNEL staining. However, in the presence of FKGK18 a concentration-dependent decrease in the incidence of apoptosis was evident. These findings are analogous to those observed in insulinoma cells and islet beta-cells, where both ER stress-induced NSMase2 expression and apoptosis were inhibited by BEL treatment [34, 43] .
In summary, our studies reveal that FKGK18 is a more potent inhibitor of iPLA 2 bthan iPLA 2 c and because, unlike BEL, it inactivates iPLA 2 b reversibly and appears to not be a non-specific inhibitor of proteases, FKGK18 may be the inhibitor of choice for in vitro, ex vivo and more importantly, in vivo studies. It is recognized that FKGK18 may have effects on other classes of non-PLA 2 enzymes and continued studies with this and future FK derivatives will reveal other, if any, non-specific effects of these compounds. The ability to identify an inhibitor of iPLA 2 b that can be used in vivo is timely and warranted because of the ever going recognition of roles for iPLA 2 b-derived products in biological processes in the context of diabetes, inflammation, and neurodegenerative and myocardial disorders. It is plausible that FKGK18 or newer generations of FK compounds could be used to prevent or delay abnormalities associated with these disease states.
Materials, Methods, and Experimental Procedures
Ethics Statement
Mice (WT and iPLA 2 b-KO breeding pairs), generously provided by Dr. John Turk (Washington University School of Medicine) were bred, maintained, and prepared for experiments according to the protocols approved by University of Alabama at Birmingham IACUC (APN# 120809160).
Reagents
Human islets were acquired from Islet Cell Resource Centers for Islet Distribution Program. FKGK18 (1,1,1-trifluoro-6-(naphthalen-2-yl)hexan-2-one) was synthesized, as previously described [29] . Other materials and (source) were as follows: La-1-palmitoyl-2-arachidonyl-[arachidonyl-1- 14 
INS-1 cell and islet culturing and treatment
INS-1 cells overexpressing iPLA 2 b (INS-1 OE) were generated and cultured as previous described [36] . Briefly, cells were cultured in RPMI 1640 medium, containing 11 mM glucose, 10% fetal calf serum, 10 mM HEPES buffer, 2 mM glutamine, 1 mM sodium pyruvate, 50 mM mercaptoethanol (BME), and 0.1% (w/v) each of penicillin and streptomycin in cell culture conditions (37uC, 5%CO 2 /95% air), as described [55] . Medium was changed every 2 days and cells were split once a week. Human islets were assessed immediately upon receipt under a microscope, non-islet matter was removed, and the islets were cultured (37uC, 5%CO 2 /95% air) for two days prior to use. Islets were also isolated from WT and iPLA 2 b-KO mice, as described [37] and cultured (37uC, 5%CO 2 /95% air) overnight prior to use. All inhibitors tested were prepared in DMSO vehicle and all experimental protocols included DMSO-only treated replicates. Of note, FKGK18 concentrations $5610 25 M caused cells to detach from the bottom of wells and die and for this reason, the concentrations of drug used were below these.
iPLA 2 enzyme activity assay
INS-1 OE cell or islet cytosol and membrane fractions were prepared and protein concentration determined using Coomassie reagent. Enzymatic Ca 2+ -independent PLA 2 activity in aliquots of cytosol or membrane fractions (30 mg of protein) was assayed by ethanolic injection (5 ml) of the substrate 16:0/[ 14 C]20:4 GPC (PAPC, 5 mM) in assay buffer (40 mM Tris, pH 7.5, and 10 mM EGTA, total volume 200 ml). Assay mixtures were incubated (3 min, 37uC, with shaking), and the assay reaction was terminated with butanol (100 ml) addition and vigorous vortexing. The reaction mixture was centrifuged (2,0006g, 5 min), and products in the upper butanol layer were analyzed by silica gel G thin-layer chromatography (TLC) in petroleum ether-ethyl ether-acetic acid (80/20/1). The TLC plate region containing free fatty acid was identified with iodine vapor, scraped, and the released 14 C fatty acid was quantitated by liquid scintillation spectrometry. Specific iPLA 2 activity was calculated from the dpm of released fatty acid and protein content, as described [32] . The assay was performed in the absence or presence of S-BEL, R-BEL, or FKGK (10 211 -10 25 M). In some studies, to verify that the measured activity reflected that of iPLA 2 b, the ability of ATP (10 mM) to stimulate activity was used as a positive control.
iPLA 2 immunoblotting analyses
Protein from cytosolic and microsomal membrane fractions was analyzed by SDS-PAGE; an equal protein load of 30 mg. The samples were run on a 10% acrylamide gel and then transferred onto Immunobolin-P PVDF membranes. Target proteins were probed with primary antibodies (iPLA2b1:200; iPLA 2 c 1:200; and GAPDH 1:500) and then with secondary antibodies (1:1000). Immunoreactive bands were visualized by enhanced chemiluminescence.
Glucose-stimulated insulin secretion and PGE2 generation
Human islets (30/condition) were incubated in 96-well round bottomed plates in MIAMI medium, supplemented with 10% fetal calf serum and 0.1% (w/v) each of penicillin and streptomycin, as described [43] . The islets were pre-treated for 1 h with KrebsRinger buffer (KRB) containing 5 mM D-glucose (5G) in the presence of vehicle only or FKGK18 (10 26 or 10 25 M). Following pre-treatment, the medium was aspirated and islets were further treated for 1 h with 5G or 20G in the presence of vehicle or FKGK18. The medium was then collected and the contents of insulin and PGE2 were determined by ELISA. Briefly, collected medium was titrated against internal standard controls of known concentrations and standard curves were then generated to calculate sample unknown concentrations for insulin (using a log standard curve) and for PGE 2 (using a 4-parameter logistics curve generated by ReaderFit software). The values were normalized to protein per sample (i.e. 30 islets) and are presented as mU/mg islet protein for insulin and pg/mg islet protein for PGE2.
Alpha-Chymotrypsin Catalyzed Cleavage Activity Assay
Bovine serum albumin (BSA, 2 mg) was reconstituted in 3 ul of 6 M Urea/50 mM Tris-HCl (pH 8). Reduction and alkylation was performed by adding 0.15 ml of 200 mM DTT/50 mM Tris-HCl (pH 8) for 1 h, and 0.6 ml of 200 mM iodoacetamide/50 mM Tris-HCl (pH 8) for 45 min in dark, respectively, at room temperature. Alkylation was quenched by adding 0.6 ml of 200 mM DTT/50 mM Tris-HCl (pH 8), and incubating for 15 min at room temperature. Twenty microliters of 1 mM CaCl 2 / 50 mM Tris-HCl (pH 7.5) was added to dilute the urea concentration down to 0.6 M. Protease inhibitors FKGK18 and/or S-BEL were added to appropriate tubes. Samples were incubated with 0.2 mg of trypsin and 0.2 mg of chymotrypsin at 37uC for 15 min, and immediately quenched by denaturing in SDS sample buffer, as per manufacturers instructions. Even volumes of each samples were loaded and separated on a 10% Bistris gel and peptide fragments were separated for 35 min at 200V constant and visualized by overnight colloidal blue staining.
Quantitative Real-time PCR
INS-1 OE cells were treated with thapsigargin (1 mM) for 8 or 24 h in the presence of vehicle or FKGK18 (10 27 -10 25 M). Total RNA was prepared using the RNeasy kit as previous [34, 35] and double stranded cDNA generated using the Superscript III Firststrand Synthesis System, as described [37, 43] . Real-time PCR was performed with Fast SYBR H Green PCR Master Mix in a platebased LightCycler H 480 System (Roche Life Sciences). The primers were designed based on published sequences for rat NSMase2 and 18S, Gene Bank #AB047002 and #X01117, respectively. Primer sets (sense/antisense) were as follows: NSMase2, ccggatgcacactacttcagaa/ggattgggtgtctggagaaca and 18S, agtcctgccctttgtacaca/gatccgagggcctcactaaac.
Apoptosis Assessment by TUNEL analyses
INS-1 OE cells were treated with vehicle or thapsigargin for 24 h in the absence or presence of FKGK18 (10 27 -10 25 M). The cells were then processed for apoptosis as described [56] using the APO-DIRECT TM kit, according to manufacturer's protocol. Briefly, cells were harvested, spun at 800g and washed in PBS preceding the addition of fixation buffer (1% (w/v) paraformaldehyde in PBS (pH 7.4). Following a 30 min incubation period on ice, the cells were washed in PBS, resuspended in 70% ethanol, and incubated for a further 30 min on ice. DNA labeling solution (Reaction Buffer, TdT Enzyme, FITC dUTP and distilled water) was then added and the cells were incubated for 1 h at 37uC. After rinsing with rinse buffer and resuspension in PI/RNase staining buffer (provided in kit), cells were incubated in the dark for 30 min at room temperature prior to flow cytometry analysis at excitation wavelength 623 nm and 520 nm for PI (staining total DNA fragmentation) and FITC-dUTP (staining apoptotic cells), respectively. Of note, FKGK18 concentrations $5610 25 M caused cells to detach and die and for this reason, the concentrations of drug used in the various analyses were #5610 25 M.
Statistical Analysis
Data were converted to mean 6 standard error of the means and the Students' t-test was applied to determine significant differences between two samples (p,0.05).
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